EUVIMEDEUVIMED entdecken
Crossref

Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States

Corey Neff, Mackenzie Price iD, Gino Cioffi, Carol Kruchko, Kristin A Waite, Jill S Barnholtz-Sloan, Quinn T Ostrom iD

Cancer · 2023

DOI: 10.1002/cncr.34837 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Corey Neff und 6 weiteren Autor:innen. Beteiligte Einrichtung: Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA. Hauptthemen laut MEDLINE: Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Musella Foundation For Brain Tumor Research and Information, Centers for Disease Control and Prevention, Pediatric Brain Tumor Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary brain tumors (BTs) are rare, but cause morbidity and mortality disproportionately to their incidence. Prevalence estimates population‐level cancer burdens at a specified time. This study estimates the prevalence of malignant and non‐malignant BTs in comparison to other cancers.

Methods

Incidence data were obtained from the Central Brain Tumor Registry of the United States (2000–2019, varying), a combined data set including the Center for Disease Control and Prevention's National Program of Cancer Registries and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Incidence of non‐BT cancers were obtained from the United States Cancer Statistics (2001–2019). Incidence and survival estimates for all cancers were obtained from SEER (1975–2018). Complete prevalence as of December 31, 2019, was estimated using prevEst . Estimates were generated overall for non‐BT cancers, by BT histopathology, age groups at prevalence (0–14, 15–39, 40–64, 65+ years), and sex.

Results

We estimated 1,323,121 individuals with a diagnosis of BTs at the date of prevalence. The majority of BT cases had non‐malignant tumors (85.3%). Among all cancers, BTs were the most prevalent cancer type among those ages 15 to 39 years, second among those ages 0 to 14 years, and in the top five among those ages 40 to 64 years. The plurality of prevalent cases (43.5%) occurred among those ages 65+ years. Overall, females had a higher prevalence of BTs than males, with an overall female:male prevalence ratio of 1.68.

Conclusions

BTs contribute significantly to the cancer burden in the United States, particularly among those younger than age 65 years. Understanding complete prevalence is crucial for monitoring cancer burden to inform clinical research and public policy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsBrain NeoplasmsMaleHumansFemaleUnited StatesInfant, NewbornAgedPrevalenceRegistriesIncidenceData ManagementSEER Program

Stichwörter der Autor:innen

Central Brain Tumor Registry of the United Statesbrain tumorcancerepidemiologyprevalence

Autor:innen und Institutionen

  • Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
  • Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
  • Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.
  • Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, Maryland, USA.
  • The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.
  • Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Mackenzie Price, Quinn T Ostrom

Förderung

  • Musella Foundation For Brain Tumor Research and Information
  • Centers for Disease Control and Prevention
  • Pediatric Brain Tumor Foundation
  • Novocure
  • Sontag Foundation
  • Uncle Kory Foundation
  • American Brain Tumor Association
  • National Brain Tumor Society

Zitieren

APA

Neff, C., Price, M., Cioffi, G., Kruchko, C., Waite, K. A., Barnholtz-Sloan, J. S., & Ostrom, Q. T. (2023). Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States. Cancer. https://doi.org/10.1002/cncr.34837

Vancouver

Neff C, Price M, Cioffi G, Kruchko C, Waite KA, Barnholtz-Sloan JS, et al. Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States. Cancer. 2023. doi:10.1002/cncr.34837

BibTeX
@article{Neff2023,
  author = {Neff, Corey and Price, Mackenzie and Cioffi, Gino and Kruchko, Carol and Waite, Kristin A and Barnholtz-Sloan, Jill S and Ostrom, Quinn T},
  title = {Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34837}
}
Kostenlos starten →